Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tellgen Corporation (300642) Fair Value & Analysis

Healthcare · CN · Market cap 2.1B CNY

Price¥12.54
Fair Value¥4.38
Upside-65.1%
Quality91/100
Evidence: High Range ¥3.46 – ¥5.31

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Tellgen Corporation (300642) currently trades at ¥12.54, while our model-based Fair Value estimate is ¥4.38 — implying the stock looks roughly 65.1% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -95% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Tellgen Corporation (300642) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥4.38 versus a price of ¥12.54 — about −65% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 300642?
Our 21-model fair value for Tellgen Corporation is ¥4.38 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥12.54.
What is the quality score of 300642?
Tellgen Corporation has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.